文献速递眼底病与葡萄膜炎

Abicipar治疗新生血管性年龄相关性黄斑变性:3期随机对照研究52周结果

Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration: 52-Week Results of Phase 3 Randomized Controlled Study.
PubMed 文献 · Ophthalmology · 2020-04-09

两项相同的3期随机双盲对照试验(CEDAR、SEQUOIA)共纳入1888例初治新生血管性AMD患者,比较abicipar Q8、Q12方案与雷珠单抗Q4方案的疗效与安全性。结果显示两种abicipar方案在52周稳定视力主要终点上均非劣于雷珠单抗,但眼内炎症不良事件发生率更高(约15% vs 0.3%)。

要点

  • abicipar Q8和Q12在52周稳定视力主要终点均非劣于雷珠单抗Q4。
  • abicipar组眼内炎症不良事件约15%,显著高于雷珠单抗组0.3%。
  • abicipar可减少治疗负担,但需关注眼内炎症风险。

核心结论

  • abicipar Q8和Q12在52周稳定视力主要终点上均非劣于雷珠单抗Q4。
  • abicipar组眼内炎症不良事件发生率高于雷珠单抗组。
  • 季度和Q8方案abicipar相比每月治疗可减少nAMD疾病和治疗负担。

研究设计与样本

  • 两项方案相同的随机、多中心、双盲、平行组、活性对照3期临床试验(CEDAR、SEQUOIA),数据汇总分析。
  • 共纳入1888例活动性脉络膜新生血管继发于AMD且研究眼BCVA为24-73个ETDRS字母的初治患者。
  • 患者按1:1:1随机分为abicipar 2mg Q8组、abicipar 2mg Q12组和雷珠单抗0.5mg Q4组。

主要发现

  • 第52周稳定视力患者比例在abicipar Q8组为93.2%、Q12组为91.3%、雷珠单抗Q4组为95.8%。
  • 第52周BCVA较基线平均变化在abicipar Q8组为7.5个字母、Q12组为6.4个字母、雷珠单抗Q4组为8.4个字母。
  • 第52周CRT较基线平均变化在abicipar Q8组为-144μm、Q12组为-145μm、雷珠单抗Q4组为-144μm。
  • 眼内炎症不良事件发生率在abicipar Q8组为15.4%、Q12组为15.3%、雷珠单抗Q4组为0.3%。
  • 眼内炎症不良事件通常为轻中度并接受局部皮质类固醇治疗,192例中62例(32.3%)接受口服和/或注射皮质类固醇。

关键数值与推荐

  • 主要疗效终点为第52周研究眼BCVA较基线丢失<15个字母的患者比例。
  • 次要终点包括第52周BCVA和CRT较基线的变化。
  • 安全性指标包括不良事件。

临床怎么用

  • abicipar Q8和Q12方案可作为减少nAMD治疗负担的选择,但需密切监测眼内炎症。
  • 出现眼内炎症不良事件时通常可使用局部皮质类固醇治疗,部分患者需口服和/或注射皮质类固醇。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare the efficacy and safety of abicipar every 8 weeks and quarterly (after initial doses) versus ranibizumab every 4 weeks in treatment-naïve patients with neovascular age-related macular degeneration (AMD). DESIGN: Two randomized, multicenter, double-masked, parallel-group, active-controlled, phase 3 clinical trials (CEDAR, SEQUOIA) with identical protocols were conducted. Data from both trials were pooled for analysis. PARTICIPANTS: Patients with active choroidal neovascularization secondary to AMD and best-corrected visual acuity (BCVA) of 24-73 Early Treatment Diabetic Retinopathy Study letters in the study eye were enrolled. METHODS: Patients (n = 1888) were randomized in a 1:1:1 ratio to study eye treatment with abicipar 2 mg every 8 weeks after 3 initial doses at baseline and weeks 4 and 8 (Q8), abicipar 2 mg every 12 weeks after 3 initial doses at baseline and weeks 4 and 12 (Q12), or ranibizumab 0.5 mg every 4 weeks (Q4). MAIN OUTCOME MEASURES: The primary efficacy end point was proportion of patients with stable vision (defined as <15-letter loss in BCVA from baseline) in the study eye at week 52. Secondary end points included change from baseline in BCVA and central retinal thickness (CRT) at week 52. Safety measures included adverse events (AEs). RESULTS: The proportion of patients with stable vision at week 52 was 93.2%, 91.3%, and 95.8% in the abicipar Q8, abicipar Q12, and ranibizumab Q4 groups, respectively, with both abicipar Q8 and Q12 noninferior to ranibizumab Q4. Week 52 mean change from baseline in BCVA was 7.5, 6.4, and 8.4 letters and in CRT was -144, -145, and -144 μm in the abicipar Q8, abicipar Q12, and ranibizumab Q4 groups, respectively. Incidence of intraocular inflammation (IOI) AEs was 15.4%, 15.3%, and 0.3%, respectively. The IOI AEs were typically mild or moderate in severity and treated with topical corticosteroids; 62 of 192 patients (32.3%) received oral and/or injectable corticosteroids. CONCLUSIONS: Abicipar Q8 and Q12 were both noninferior to ranibizumab Q4 in the primary end point of stable vision at week 52. Intraocular inflammation was more frequent with abicipar. Quarterly and Q8 abicipar reduce nAMD disease and treatment burden compared with monthly treatment.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Kunimoto D, Yoon YH, Wykoff CC, et al. Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration: 52-Week Results of Phase 3 Randomized Controlled Study. Ophthalmology. 2020. PMID: 32471729. doi:10.1016/j.ophtha.2020.03.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。